Treace Medical Concepts Reports Second Quarter 2024 Financial Results

Rhea-AI Summary

Treace Medical Concepts (NASDAQ: TMCI) reported its Q2 2024 financial results, showing revenue growth of 6% to $44.5 million compared to Q2 2023. The company's gross margin was 80.2%, slightly down from 81.7% in the previous year. Despite revenue growth, Treace faced a net loss of $21.2 million, or ($0.34) per share, wider than the $12.3 million loss in Q2 2023. The increased loss was attributed to higher operating expenses, which rose to $57.1 million from $47.3 million year-over-year. Treace maintains a strong cash position of $97.0 million and reaffirmed its full-year 2024 revenue guidance of $201-$211 million, representing 7-13% growth. The company expects Adjusted EBITDA to improve by approximately 50% compared to 2023.

Positive

• Revenue increased by 6% year-over-year to $44.5 million
• Gross margin remained strong at 80.2%
• Patent portfolio expanded to 65 granted U.S. patents
• Active surgeon base increased
• Company reaffirmed full-year 2024 revenue guidance of $201-$211 million
• Adjusted EBITDA expected to improve by approximately 50% in 2024

Negative

• Net loss widened to $21.2 million from $12.3 million in Q2 2023
• Operating expenses increased significantly to $57.1 million from $47.3 million
• Gross margin decreased from 81.7% to 80.2% year-over-year
• Adjusted EBITDA loss increased to $8.7 million from $7.7 million in Q2 2023

Financial Analyst

Treace Medical Concepts' Q2 2024 results show mixed signals. While revenue increased 6% year-over-year to $44.5 million, the company reported a wider net loss of ($21.2) million compared to ($12.3) million in Q2 2023. The gross margin slightly decreased to 80.2% from 81.7% last year.

The company's increased operating expenses of $57.1 million, up from $47.3 million, reflect strategic investments in sales, product innovation and corporate initiatives. This aggressive spending strategy aims to capture market share but is currently pressuring profitability.

With $97.0 million in cash and equivalents, Treace appears to have sufficient liquidity to fund its growth initiatives. The reaffirmed full-year 2024 revenue guidance of $201 million to $211 million suggests management's confidence in future growth despite current challenges.

Medical Research Analyst

Treace's focus on bunion and midfoot deformity treatments through its Lapiplasty® and Adductoplasty® Procedures represents a niche market with growth potential. The expansion of their patent portfolio to 65 U.S. patents and 22 international patents strengthens their intellectual property position, potentially creating barriers to entry for competitors.

The planned entry into the minimally invasive metatarsal osteotomy market in Q4 2024 could open up new revenue streams. This move aligns with the trend towards less invasive surgical procedures, which often lead to faster recovery times and improved patient outcomes.

However, the company's reliance on a base of over 3,000 active surgeons highlights the importance of surgeon adoption and training. The success of new product launches will largely depend on effectively educating and onboarding surgeons to these new technologies.

Market Research Analyst

The 6% revenue growth in Q2 2024 suggests Treace is maintaining its market position but facing challenges in accelerating growth. The company's strategy of focusing on product mix shift and increasing adoption of newer technologies appears to be yielding results, albeit modestly.

The planned entry into the minimally invasive metatarsal osteotomy market in Q4 is a strategic move to diversify revenue streams. However, as a "relatively nascent" market, it may require significant investment in education and marketing to drive adoption.

Treace's ability to improve its Adjusted EBITDA by approximately 50% for full-year 2024, as projected, will be important to watch. This improvement, if achieved, could signal better operational efficiency and potentially lead to improved investor confidence in the company's long-term profitability prospects.

PONTE VEDRA, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty^® and Adductoplasty^® Procedures, today reported financial results for the second quarter ended June 30, 2024.

Recent Highlights

• Revenue of $44.5 million in second quarter 2024 increased 6% over same period in 2023
• Gross margin of 80.2% in second quarter 2024
• Patent portfolio expands to 65 granted U.S. patents, with an additional 22 granted patents worldwide and 84 pending U.S. patent applications

John T. Treace, CEO and Founder of Treace, said, "Second quarter results came in as expected. We remain focused on capturing an even larger share of procedure volumes from our base of over 3,000 active surgeons with several new planned product launches in the second half of 2024, including our entry into the relatively nascent minimally invasive metatarsal osteotomy market in Q4. We are confident in our strategic investments in our growing portfolio of innovative, reproducible solutions for a dynamic bunion market, supporting our market position and long-term outlook.”

Second Quarter 2024 Financial Results

Revenue for the second quarter of 2024 was $44.5 million, representing an increase of 6% compared to $42.0 million in the second quarter of 2023. The increase was driven by product mix shift that resulted from increased adoption of newer technologies and increased sales of complementary products used in bunion and related midfoot procedures as well as increases in our active surgeon base.

Gross profit for the second quarter of 2024 was $35.7 million compared to a gross profit of $34.3 million in the second quarter of 2023. Gross margin totaled 80.2% in the second quarter of 2024, compared to 81.7% in the second quarter of 2023, primarily due to a shift in product mix, increases in payroll and inventory provisions, partially offset by lower royalty rates.

Total operating expenses were $57.1 million in the second quarter of 2024, compared to total operating expenses of $47.3 million in the second quarter of 2023. Increased operating expenses in the second quarter of 2024, including share-based compensation expense, reflect strategic investments in the Company’s expanding direct sales channel, investments in product innovation, customer credit loss, and support for other corporate initiatives.

Second quarter 2024 net loss attributable to common stockholders was ($21.2) million, or ($0.34) per share, compared to ($12.3) million, or ($0.20) per share, for the same period in 2023. Adjusted EBITDA loss was ($8.7) million in the second quarter of 2024 compared to a loss of ($7.7) million for the same period in 2023. See below for additional information and a reconciliation of non-GAAP financial information.

Cash, cash equivalents, marketable securities and investment receivable totaled $97.0 million as of June 30, 2024. The Company believes it has sufficient balance sheet strength and flexibility to continue effectively executing on its strategic investments and growth initiatives for the foreseeable future.

Financial Outlook

The Company is reaffirming full-year 2024 revenue guidance of $201 million to $211 million, representing growth of 7% to 13%, compared to full-year 2023.

The Company continues to expect Adjusted EBITDA to improve approximately 50% compared to full-year 2023.*

* A reconciliation of Adjusted EBITDA to GAAP net loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.

Webcast and Conference Call Details

Treace will host a conference call today, August 6, 2024, at 4:30 p.m. ET to discuss its second quarter 2024 financial results. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. The live webcast of the conference call will be available on the Investor Relations section of the Company’s website at investors.treace.com. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures

To supplement the financial results presented in accordance with GAAP, this earnings release presents Adjusted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs, restructuring costs, customer credit loss, and debt extinguishment loss. Non-GAAP financial measures such as Adjusted EBITDA are presented in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management uses non-GAAP financial measures to evaluate the Company’s operating performance and trends, as well as for making planning decisions. The Company believes that Adjusted EBITDA helps to identify underlying trends in the Company’s business that may otherwise be masked by the effect of the income and expenses and other items that it excludes in its calculation of Adjusted EBITDA. Accordingly, the Company believes this non-GAAP financial measure provides useful information to investors and others in understanding and evaluating the Company’s operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by the Company’s management in their financial and operational decision-making. The Company also presents this non-GAAP financial measure because it believes investors, analysts and rating agencies consider it to be a useful metric in measuring the Company’s performance against other companies and its ability to meet its debt service obligations.

There are limitations related to the use of non-GAAP financial measures such as Adjusted EBITDA because they are not prepared in accordance with GAAP, may exclude significant income and expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation between GAAP and non-GAAP results is presented below.

Forward-Looking Statements

This press release and statements made during the Company’s earnings call contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, the Company’s: revenue guidance and estimated revenue growth rates for full-year 2024; estimated quarterly revenue growth rates; ability to effectively respond to and mitigate the impact of challenges in the current market environment, including in response to increased competition and accelerating adoption of MIS osteotomy solutions; ability to effectively reduce costs and right size the Company’s P&L and the future impact of the right sizing; anticipated future product launches and the timing of such product launches, including its planned 3D MIS osteotomy platforms; ability to increase its procedure volumes and gain market share; strategic investments supporting its market position and long-term outlook; ability to protect and enforce its intellectual property rights; success in defending against infringement of its intellectual property by third parties, including its competitors; expected seasonality; anticipated pace of growth in the foot and ankle market; sufficient balance sheet strength and flexibility to continue effectively executing on its strategic investments and growth initiatives for the foreseeable future; anticipated liquidity; and expectation of progress in Adjusted EBITDA for full-year 2024 and expected rate of Adjusted EBITDA improvement. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024, and its subsequent SEC filings. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise. The Company’s results for the quarter ended June 30, 2024 are not necessarily indicative of its operating results for any future periods.

Internet Posting of Information

Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty^® 3D Bunion Correction^® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty^® Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty^® and Adductoplasty^® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.

To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.

Contacts:

Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net

Treace Medical Concepts, Inc. Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (unaudited)
	Three Months Ended June 30,								Six Months Ended June 30,
	2024				2023				2024				2023
Revenue	$	44,455			$	41,953			$	95,563			$	84,148
Cost of goods sold		8,781				7,675				18,908				15,714
Gross profit		35,674				34,278				76,655				68,434
Operating expenses
Sales and marketing		37,681				33,773				78,009				67,428
Research and development		5,157				3,526				10,416				6,938
General and administrative		14,218				10,031				28,580				20,896
Total operating expenses		57,056				47,330				117,005				95,262
Loss from operations		(21,382	)			(13,052	)			(40,350	)			(26,828	)
Interest income		1,376				1,968				2,911				3,447
Interest expense		(1,312	)			(1,282	)			(2,629	)			(2,567	)
Other income, net		112				95				186				223
Other non-operating income (expense), net		176				781				468				1,103
Net loss	$	(21,206	)		$	(12,271	)		$	(39,882	)		$	(25,725	)
Other comprehensive income (loss)
Unrealized gain (loss) on marketable securities	$	(95	)		$	(163	)		$	(189	)		$	(192	)
Comprehensive loss	$	(21,301	)		$	(12,434	)		$	(40,071	)		$	(25,917	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.34	)		$	(0.20	)		$	(0.64	)		$	(0.43	)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted		62,081,494				61,382,514				61,937,140				60,060,483

Treace Medical Concepts, Inc. Balance Sheets (in thousands, except share and per share amounts) (unaudited)
	June 30,				December 31,
	2024				2023
Assets
Current assets
Cash and cash equivalents	$	18,181			$	12,982
Marketable securities, short-term		76,865				110,216
Accounts receivable, net of allowance for credit losses of $978 and $980 as of June 30, 2024 and December 31, 2023, respectively		25,559				38,063
Inventories		41,279				29,245
Prepaid expenses and other current assets		9,668				7,853
Total current assets		171,552				198,359
Property and equipment, net		24,245				22,298
Intangible assets, net of accumulated amortization of $950 and $475 as of June 30, 2024 and December 31, 2023, respectively		8,550				9,025
Goodwill		12,815				12,815
Operating lease right-of-use assets		8,775				9,264
Other non-current assets		146				146
Total assets	$	226,083			$	251,907
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$	18,073			$	11,835
Accrued liabilities		13,730				10,458
Accrued commissions		5,931				10,759
Accrued compensation		6,192				7,549
Other liabilities		520				4,432
Total current liabilities		44,446				45,033
Long-term debt, net of discount of $843 and $992 as of June 30, 2024 and December 31, 2023, respectively		53,157				53,008
Operating lease liabilities, net of current portion		16,302				15,891
Other long-term liabilities		37				37
Total liabilities		113,942				113,969
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred stock, $0.001 par value, 5,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 0 shares issued and outstanding as of June 30, 2024 and December 31, 2023		—				—
Common stock, $0.001 par value, 300,000,000 shares authorized; 62,194,845 and 61,749,654 issued, and 62,175,241 and 61,749,654 outstanding as of June 30, 2024 and December 31, 2023, respectively		62			62
Additional paid-in capital		286,484				271,973
Accumulated deficit		(174,129	)			(134,247	)
Accumulated other comprehensive (loss) income		(26	)			163
Treasury stock, at cost; 19,604 and 1,218 shares as of June 30, 2024 and December 31, 2023, respectively		(250	)			(13	)
Total stockholders’ equity		112,141				137,938
Total liabilities and stockholders’ equity	$	226,083			$	251,907

Treace Medical Concepts, Inc. Statements of Cash Flows (in thousands) (unaudited)
	Six Months Ended June 30,
	2024				2023
Cash flows from operating activities
Net loss	$	(39,882	)		$	(25,725	)
Adjustments to reconcile net loss to net cash used in operating    activities
Depreciation and amortization expense		4,025				2,019
Provision for allowance for credit losses		2,207				78
Share-based compensation expense		14,148				6,288
Non-cash lease expense		1,182				1,264
Amortization of debt issuance costs		149				148
Accretion (amortization) of discount (premium) on marketable securities, net		(685	)			(663	)
Other, net		159				5
Net changes in operating assets and liabilities, net of acquisitions
Accounts receivable		10,297				1,886
Inventory		(12,034	)			(6,704	)
Prepaid expenses and other assets		185				(1,641	)
Operating lease liabilities		(1,291	)			1,072
Accounts payable		6,238				(522	)
Accrued liabilities		(5,943	)			(3,137	)
Other, net		127				38
Net cash used in operating activities		(21,118	)			(25,594	)
Cash flows from investing activities
Purchases of available-for-sale marketable securities		(28,711	)			(120,957	)
Sales and maturities of available-for-sale marketable securities		60,558				55,763
Purchases of property and equipment		(5,656	)			(5,709	)
Acquisition, net of cash acquired		—				(20,000	)
Net cash provided by (used in) investing activities		26,191				(90,903	)
Cash flows from financing activities
Proceeds from issuance of common stock from public offering, net of issuance costs and underwriting discount of $7.5 million		—				107,527
Proceeds from exercise of employee stock options		363				1,532
Taxes from withheld shares		(237	)			—
Net cash provided by (used in) financing activities		126				109,059
Net increase (decrease) in cash and cash equivalents		5,199				(7,438	)
Cash and cash equivalents at beginning of period		12,982				19,473
Cash and cash equivalents at end of period	$	18,181			$	12,035
Supplemental disclosure of cash flow information
Cash paid for interest	$	2,490			$	2,567
Operating lease right-of-use asset and lease liability adjustment due to lease incentive	$	86			$	(13	)
Noncash investing activities
Unrealized (gains) losses, net on marketable securities	$	189			$	192
Unsettled matured marketable security and receivable from broker	$	2,000			$	—

Treace Medical Concepts, Inc. Reconciliation of GAAP Net Loss to EBITDA & Adjusted EBITDA (in thousands) (unaudited)
	Three Months Ended June 30,								Six Months Ended June 30,
	2024				2023				2024				2023
Net loss	$	(21,206	)		$	(12,271	)		$	(39,882	)		$	(25,725	)
Adjustments:
Interest income		(1,376	)			(1,968	)			(2,911	)			(3,447	)
Interest expense		1,312				1,282				2,629				2,567
Taxes		—				—				—				—
Depreciation & Amortization		2,116				1,095				4,025				2,019
EBITDA	$	(19,154	)		$	(11,862	)		$	(36,139	)		$	(24,586	)
Share-based compensation expense		6,740				3,596				14,148				6,288
Acquisition-related costs		556				520				1,873				520
Restructuring costs1		964				—				964				—
Customer credit loss2		2,147				—				2,147				—
Adjusted EBITDA	$	(8,747	)		$	(7,746	)		$	(17,007	)		$	(17,778	)

¹ Restructuring charges primarily relate to severance payments and other post-employment benefits from a restructuring in June 2024.
² Customer credit loss consists of the write-off of accounts receivable due from a customer that filed for bankruptcy during the second quarter of 2024.

FAQ

What was Treace Medical Concepts' (TMCI) revenue for Q2 2024?

Treace Medical Concepts reported revenue of $44.5 million for Q2 2024, representing a 6% increase compared to the same period in 2023.

How did Treace Medical Concepts' (TMCI) net loss change in Q2 2024 compared to Q2 2023?

Treace Medical Concepts' net loss widened to $21.2 million in Q2 2024, compared to $12.3 million in Q2 2023. This represents a loss of ($0.34) per share in Q2 2024, up from ($0.20) per share in Q2 2023.

What is Treace Medical Concepts' (TMCI) revenue guidance for full-year 2024?

Treace Medical Concepts reaffirmed its full-year 2024 revenue guidance of $201 million to $211 million, representing growth of 7% to 13% compared to full-year 2023.

How many active surgeons does Treace Medical Concepts (TMCI) have in its base?

Treace Medical Concepts reported having a base of over 3,000 active surgeons.